Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population
Steven Kozlowski1, Natasha Flowers2, Noy Birger2
1Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Steven.Kozlowski@fda.hhs.gov.
No abstract available in PubMed .
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
